In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
Z Haider, Muhammad Muneeb Subhani, Muhammad Ansar Farooq, Maryum Ishaq, Maryam Khalid, Muhammad Numan Akram, Rao Sohail Ahmad Khan, Adnan Khan Niazi · PubMed · 2020
of SARS-CoV-2 and strong inhibition effect than the N3 (reference inhibitor). A good binding energy, drug likeness and effective pharmacokinetic parameters suggest that these candidates have greater potential to stop the replication of SARS-CoV-2, hence might lead to the cure of COVID-19.